Skip to Main Content

Author Details

Jeffrey D Lifson
Frederick National Laboratory
1977
465
107
Nevan J Krogan (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36894436Programming cytomegalovirus as an HIV vaccine.Trends Immunol2023
37662237CD4 T cell Responses in the CNS during SIV infection.bioRxiv2023
37625266Long-acting lenacapavir protects macaques against intravenous challenge with simian-tropic HIV.EBioMedicine2023
38060615Deep analysis of CD4 T cells in the rhesus CNS during SIV infection.PLoS Pathog2023
37993716HIV-1 Env trimers asymmetrically engage CD4 receptors in membranes.Nature2023
37693567CCR7+ CD4 T Cell Immunosurveillance Disrupted in Chronic SIV-Induced Neuroinflammation in Rhesus Brain.bioRxiv2023
37783968AZD5582 plus SIV-specific antibodies reduce lymph node viral reservoirs in antiretroviral therapy-suppressed macaques.Nat Med2023
38091409Lymphoid tissues contribute to plasma viral clonotypes early after antiretroviral therapy interruption in SIV-infected rhesus macaques.Sci Transl Med2023
37418480Correction: Tracking the Luminal Exposure and Lymphatic Drainage Pathways of Intravaginal and Intrarectal Inocula Used in Nonhuman Primate Models of HIV Transmission.PLoS One2023
37205470SIV clearance from neonatal macaques following transient CCR5 depletion.bioRxiv2023
37398418Lymphoid tissues contribute to viral clonotypes present in plasma at early post-ATI in SIV-infected rhesus macaques.bioRxiv2023
34986348Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys.Cell Rep2022
35714200Myeloid cell tropism enables MHC-E-restricted CD8<sup>+</sup> T cell priming and vaccine efficacy by the RhCMV/SIV vaccine.Sci Immunol2022
35714165A cellular trafficking signal in the SIV envelope protein cytoplasmic domain is strongly selected for in pathogenic infection.PLoS Pathog2022
35967461Highly Efficient Autologous HIV-1 Isolation by Coculturing Macrophage With Enriched CD4<sup>+</sup> T Cells From HIV-1 Patients.Front Virol2022
36068229Molecular insights into antibody-mediated protection against the prototypic simian immunodeficiency virus.Nat Commun2022
36030289Limited impact of fingolimod treatment during the initial weeks of ART in SIV-infected rhesus macaques.Nat Commun2022
35981532Cytomegalovirus-vaccine-induced unconventional T cell priming and control of SIV replication is conserved between primate species.Cell Host Microbe2022
36344847Cryo-EM structures of prefusion SIV envelope trimer.Nat Struct Mol Biol2022
35316218Rapamycin limits CD4+ T cell proliferation in simian immunodeficiency virus-infected rhesus macaques on antiretroviral therapy.J Clin Invest2022
35041707The ingenol-based protein kinase C agonist GSK445A is a potent inducer of HIV and SIV RNA transcription.PLoS Pathog2022
35080914Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy.Sci Transl Med2022
33465055Antibody-mediated depletion of viral reservoirs is limited in SIV-infected macaques treated early with antiretroviral therapy.J Clin Invest2021
33910957Recombinant Herpesvirus Vectors: Durable Immune Responses and Durable Protection against Simian Immunodeficiency Virus SIVmac239 Acquisition.J Virol2021
33796119Non-neutralizing Antibodies May Contribute to Suppression of SIVmac239 Viremia in Indian Rhesus Macaques.Front Immunol2021
33766941Modulation of MHC-E transport by viral decoy ligands is required for RhCMV/SIV vaccine efficacy.Science2021
33766849Cytomegaloviral determinants of CD8[+] T cell programming and RhCMV/SIV vaccine efficacy.Sci Immunol2021
33568515CD8 lymphocyte depletion enhances the latency reversal activity of the SMAC mimetic AZD5582 in ART-suppressed SIV-infected rhesus macaques.J Virol2021
33536176Evaluating a New Class of AKT/mTOR Activators for HIV Latency Reversing Activity <i>Ex Vivo and In Vivo</i>.J Virol2021
33658341New SHIVs and Improved Design Strategy for Modeling HIV-1 Transmission, Immunopathogenesis, Prevention and Cure.J Virol2021
33630764CD8+ T cells fail to limit SIV reactivation following ART withdrawal until after viral amplification.J Clin Invest2021
34623326Concordance of immunological events between intrarectal and intravenous SHIVAD8-EO infection when assessed by Fiebig-equivalent staging.J Clin Invest2021
34477118Prevalence and risk of residual viremia after ART in low- and middle-income countries: A cross-sectional study.Medicine (Baltimore)2021
34143853Transient viral replication during analytical treatment interruptions in SIV infected macaques can alter the rebound-competent viral reservoir.PLoS Pathog2021
34001890IL-21 and IFNα therapy rescues terminally differentiated NK cells and limits SIV reservoir in ART-treated macaques.Nat Commun2021
34228762Interleukin-15 response signature predicts RhCMV/SIV vaccine efficacy.PLoS Pathog2021
31562760Recombinant Human Interleukin-15 and Anti-PD-L1 Combination Therapy Expands a CXCR3+PD1-/low CD8 T-Cell Subset in Simian Immunodeficiency Virus-Infected Rhesus Macaques.J Infect Dis2020
31843933Genetically barcoded SIV reveals the emergence of escape mutations in multiple viral lineages during immune escape.Proc Natl Acad Sci U S A2020
32083148Induction of Transient Virus Replication Facilitates Antigen-Independent Isolation of SIV-Specific Monoclonal Antibodies.Mol Ther Methods Clin Dev2020
33028714Rectal Acquisition of Simian Immunodeficiency Virus (SIV) SIVmac239 Infection despite Vaccine-Induced Immune Responses against the Entire SIV Proteome.J Virol2020
32690707Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody.Proc Natl Acad Sci U S A2020
32601441Subnanometer structures of HIV-1 envelope trimers on aldrithiol-2-inactivated virus particles.Nat Struct Mol Biol2020
32817214SMAC Mimetic Plus Triple-Combination Bispecific HIVxCD3 Retargeting Molecules in SHIV.C.CH505-Infected, Antiretroviral Therapy-Suppressed Rhesus Macaques.J Virol2020
32284611CTLA-4 and PD-1 dual blockade induces SIV reactivation without control of rebound after antiretroviral therapy interruption.Nat Med2020
32302364Loss of tetherin antagonism by Nef impairs SIV replication during acute infection of rhesus macaques.PLoS Pathog2020
32130229Immunotherapy with DNA vaccine and live attenuated rubella/SIV gag vectors plus early ART can prevent SIVmac251 viral rebound in acutely infected rhesus macaques.PLoS One2020
32256496Long-Term Delivery of an Anti-SIV Monoclonal Antibody With AAV.Front Immunol2020
30381490Dolutegravir Monotherapy of Simian Immunodeficiency Virus-Infected Macaques Selects for Several Patterns of Resistance Mutations with Variable Virological Outcomes.J Virol2019
31830058Toll-like receptor 7-adapter complex modulates interferon-α production in HIV-stimulated plasmacytoid dendritic cells.PLoS One2019
31653683Role of IL-15 Signaling in the Pathogenesis of Simian Immunodeficiency Virus Infection in Rhesus Macaques.J Immunol2019
  • 1 - 50 of 465

Recommended Authors

Blake Frey
University of Alabama at Birmingham
Career Start Year 2014
Number of shared co-authors 2
Amy L Ellis-Connell
University of Wisconsin
Career Start Year 2010
Number of shared co-authors 2
Kei Sato
The Institute of Medical Science, The University of Tokyo
Career Start Year 2008
Number of shared co-authors 2
Cherie T Ng
The Scripps Research Institute
Career Start Year 2004
Number of shared co-authors 1
Claudia T Flynn
The Scripps Research Institute
Career Start Year 2004
Number of shared co-authors 1
Samir K Lakhashe
Texas Biomedical Research Institute
Career Start Year 2002
Number of shared co-authors 4
Alberto Bosque
George Washington University
Career Start Year 2000
Number of shared co-authors 8
Edward P Browne
University of North Carolina at Chapel Hill
Career Start Year 2000
Number of shared co-authors 0
Maudi Killian
University of California San Francisco
Career Start Year 1999
Number of shared co-authors 10
Viviana Simon
Icahn School of Medicine at Mount Sinai
Career Start Year 1997
Number of shared co-authors 7
Benhur Lee
Icahn School of Medicine at Mount Sinai
Career Start Year 1995
Number of shared co-authors 9
Greg J Towers
University College London
Career Start Year 1995
Number of shared co-authors 6
Ulf Dittmer
University Hospital Essen, University of Duisburg-Essen, Institute for Virology
Career Start Year 1993
Number of shared co-authors 11
Vicente Planelles
University of Utah
Career Start Year 1991
Number of shared co-authors 9
Ronald G Collman
University of Pennsylvania School of Medicine
Career Start Year 1988
Number of shared co-authors 9
Rafael Delgado
Instituto de Investigacion Hospital 12 de Octubre (imas12)
Career Start Year 1988
Number of shared co-authors 4
Ian Frank
IF School of Medicine, University of Pennsylvania
Career Start Year 1987
Number of shared co-authors 20
David B Weiner
Wistar Institute
Career Start Year 1986
Number of shared co-authors 10
Michael C Keefer
MK University of Rochester
Career Start Year 1986
Number of shared co-authors 7
Mohan Somasundaran
University of Massachusetts Chan Medical School
Career Start Year 1985
Number of shared co-authors 2
Ann C Collier
University of Washington
Career Start Year 1984
Number of shared co-authors 15
Stephen Raffanti
Vanderbilt University Medical Center
Career Start Year 1983
Number of shared co-authors 2
Michael Emerman
Fred Hutchinson Cancer Center
Career Start Year 1982
Number of shared co-authors 12
Timothy R Fouts
Profectus BioSciences Inc.
Career Start Year 1981
Number of shared co-authors 3
Donald S Burke
Graduate School of Public Health, University of Pittsburghgrid.21925.3d
Career Start Year 1976
Number of shared co-authors 3
Robert F Garry
Tulane University School of Medicine
Career Start Year 1974
Number of shared co-authors 1
Joseph B Margolick
Johns Hopkins Bloomberg School of Public Health
Career Start Year 1973
Number of shared co-authors 18
Ronald Swanstrom
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Career Start Year 1972
Number of shared co-authors 15
Eric Hunter
Center for Family Health Research Zambia
Career Start Year 1971
Number of shared co-authors 16
Luis J Montaner
Wistar Institute
Career Start Year 1958
Number of shared co-authors 13

Collaborators

Brandon F Keele
Co-authored papers 58
Jacob D Estes
Vaccine and Gene Therapy Institute, Oregon Health & Science University
Co-authored papers 54
Louis J Picker
Vaccine and Gene Therapy Institute, Oregon Health & Science University
Co-authored papers 33
David C Montefiori
Co-authored papers 27
David I Watkins
Co-authored papers 25
Mary Carrington
Frederick National Laboratory for Cancer Research, National Cancer Institute
Co-authored papers 16
George M Shaw
Co-authored papers 14
Afam A Okoye
Vaccine & Gene Therapy Institute, and Oregon National Primate Research Center
Co-authored papers 13
Beatrice H Hahn
Co-authored papers 13
Jason M Brenchley
National Institute of Allergy and Infectious Diseases, National Institutes of Health
Co-authored papers 12
Steven G Deeks
University of California san francisco
Co-authored papers 12
John R Mascola
Co-authored papers 11
Theodora Hatziioannou
The Rockefeller University
Co-authored papers 10
David H O'Connor
Co-authored papers 9
Steven M Wolinsky
Northwestern University Feinberg School of Medicine
Co-authored papers 9
Galit Alter
Co-authored papers 9
Paul D Bieniasz
The Rockefeller University
Co-authored papers 9
Zandrea Ambrose
Co-authored papers 8
Steven E Bosinger
Co-authored papers 7
Jay A Nelson
Oregon Health and Science University
Co-authored papers 7
Francois Villinger
Co-authored papers 7
Celia C LaBranche
Co-authored papers 7
Jason Dufour
Co-authored papers 6
Guangping Gao
Co-authored papers 6
Peter D Kwong
Co-authored papers 6
Pamela A Kozlowski
Co-authored papers 6
Bruce D Walker
Ragon Institute of Mass General
Co-authored papers 6
Marcus Altfeld
Co-authored papers 6
Dan H Barouch
Co-authored papers 6
Rafick-Pierre Sekaly
Pathology Advanced Translational Research Unit, Emory University School of Medicine
Co-authored papers 6
Release 1.2